DealsMay 4, 2026, 04:39 PM
SAB Biotherapeutics Secures $36M Manufacturing Deal for SAB-142
AI Summary
SAB Biotherapeutics, Inc. entered into a Master Manufacturing Services Agreement with Emergent BioSolutions Canada Inc. for the clinical and commercial manufacturing of its product, SAB-142. The agreement, effective April 28, 2026, has a term of five years post-FDA approval of SAB-142 and includes a minimum aggregate spend of $36 million following approval. Emergent will be the exclusive manufacturer, with provisions for SAB to establish an alternative source under limited conditions, securing a critical step for product commercialization.
Key Highlights
- Master Manufacturing Services Agreement signed with Emergent BioSolutions Canada Inc.
- Emergent to provide clinical and commercial manufacturing for SAB-142.
- Agreement term is 5 years from SAB-142's FDA approval date.
- Minimum aggregate spend of $36 million following FDA approval.
- Emergent granted exclusive manufacturing rights for SAB-142.